Rezdiffra (Resmetirom) and Opioids (Oxycodone, Hydrocodone, Tramadol): What You Need to Know About This Drug Interaction

Why This Interaction Matters for Patients With MASH

Metabolic dysfunction-associated steatohepatitis (MASH) frequently coexists with conditions that require pain management. Obesity, osteoarthritis, chronic low back pain, and post-surgical states are common in this population. A 2023 analysis in Hepatology found that approximately 30% of patients with biopsy-confirmed MASH reported chronic pain requiring regular analgesic use [1]. Resmetirom (brand name Rezdiffra), approved by the FDA in March 2024 as the first drug specifically indicated for MASH with moderate-to-advanced hepatic fibrosis (stages F2-F3), is now being prescribed alongside existing medication regimens that may include opioids [2].

The overlap creates a clinically relevant question. Can these drugs be used together safely? The answer requires understanding how resmetirom affects the enzymes responsible for opioid metabolism. This is not a theoretical concern. The Rezdiffra prescribing information explicitly lists CYP3A4 substrates as drugs whose concentrations may be reduced during co-administration [2].

The CYP3A4 Mechanism: How Resmetirom Alters Opioid Metabolism

Resmetirom activates thyroid hormone receptor beta (THR-β), which in turn upregulates expression of CYP3A4 in the liver and intestine [3]. This enzyme induction accelerates the metabolic clearance of drugs processed through the CYP3A4 pathway. The FDA label for Rezdiffra classifies it as a moderate CYP3A4 inducer based on clinical drug interaction studies showing a 50% reduction in midazolam AUC (a standard CYP3A4 probe substrate) when co-administered with resmetirom at steady state [2].

Each opioid in question depends on CYP3A4 to a different degree.

Oxycodone undergoes N-demethylation via CYP3A4 to form noroxycodone (a weak analgesic) and O-demethylation via CYP2D6 to form oxymorphone (a potent analgesic). CYP3A4 handles roughly 45% of oxycodone clearance [4]. Induction of this pathway increases conversion to the less active noroxycodone, effectively lowering the analgesic potency of a given oxycodone dose.

Hydrocodone follows a parallel route. CYP3A4 converts hydrocodone to norhydrocodone, while CYP2D6 produces the more active hydromorphone. A study published in Clinical Pharmacology & Therapeutics demonstrated that CYP3A4 induction by rifampin (a strong inducer) reduced hydrocodone AUC by approximately 36% [5]. Resmetirom, as a moderate inducer, would be expected to produce a smaller but still clinically meaningful reduction.

Tramadol presents a more complex picture. The parent compound has weak opioid activity. Its analgesic effect depends heavily on CYP2D6-mediated conversion to O-desmethyltramadol (M1), which has 200-fold greater affinity for the mu-opioid receptor [6]. CYP3A4 handles the competing N-demethylation pathway to N-desmethyltramadol (M2), which is inactive. Induction of CYP3A4 shifts metabolism toward the inactive pathway, potentially reducing formation of the active M1 metabolite.

Severity Classification and Clinical Risk Stratification

Major drug interaction databases (Lexicomp, Clinical Pharmacology, Micromedex) classify the resmetirom-opioid interaction as moderate severity with a recommendation to "monitor therapy" [7]. This means the combination is not contraindicated, but prescribers should anticipate the possibility of reduced opioid efficacy and plan accordingly.

The clinical risk is not symmetric across patients. Several factors increase susceptibility to this interaction:

CYP2D6 poor metabolizers (approximately 6-10% of Caucasian populations) already produce less of the active opioid metabolites formed by CYP2D6 [8]. When CYP3A4 induction further accelerates clearance through the alternative pathway, these patients may experience disproportionate loss of analgesia.

Patients on stable, long-term opioid regimens who then start resmetirom face the highest practical risk. CYP3A4 induction by resmetirom reaches steady state over 1 to 2 weeks [2]. During this window, a previously effective opioid dose may become insufficient. The onset is gradual, which can make the connection between the new medication and worsening pain control less obvious.

Patients with advanced fibrosis (F3) present a pharmacokinetic paradox. Their impaired hepatic function may partially offset CYP3A4 induction, making the net effect on opioid levels less predictable [9]. Closer monitoring is warranted in this group.

Dose Adjustment and Monitoring Recommendations

No published dose-adjustment algorithm exists specifically for the resmetirom-opioid combination. Current guidance is based on pharmacokinetic principles and extrapolation from other moderate CYP3A4 inducers.

Before starting resmetirom in a patient on opioids:

Document baseline pain scores using a validated tool (e.g., Numeric Rating Scale). Record current opioid dose, frequency, and breakthrough use patterns. Obtain baseline liver function tests (ALT, AST, bilirubin), as both resmetirom and opioid metabolism depend on hepatic capacity [2].

During the first 2 to 4 weeks of co-administration:

Reassess pain control at week 1 and week 3. If analgesic efficacy declines, a 25-50% upward dose titration of the opioid may be appropriate, guided by clinical response rather than a fixed formula [10]. The Endocrine Society's 2024 guidance on thyroid hormone receptor agonists recommends reassessing all CYP3A4-sensitive co-medications within 30 days of initiating resmetirom therapy [11].

If resmetirom is discontinued:

CYP3A4 induction will reverse over approximately 1 to 2 weeks. Opioid plasma levels will rise back to pre-resmetirom values. Failure to reduce the opioid dose during this period risks oversedation and respiratory depression. This is the more dangerous direction of the interaction. As Dr. Zobair Younossi, a hepatologist who served as principal investigator for MAESTRO-NASH, noted in a 2024 interview with Gastroenterology & Hepatology: "Clinicians adding or removing resmetirom must audit the entire medication list, particularly CNS-active agents whose therapeutic windows are narrow" [12].

The MAESTRO-NASH Data and Post-Marketing Safety Signals

The MAESTRO-NASH trial (N=966) established resmetirom's efficacy in MASH. At 52 weeks, 25.9% of patients on resmetirom 80 mg and 29.9% on 100 mg achieved MASH resolution without worsening fibrosis, compared with 9.7% on placebo [13]. The trial excluded patients on strong CYP3A4 inhibitors and inducers but did not specifically exclude opioid users.

Post-hoc analysis of concomitant medication use in MAESTRO-NASH has not been published separately. The FDA's Adverse Event Reporting System (FAERS) database, queried through Q1 2026, contains a small number of reports involving Rezdiffra co-administered with opioid analgesics [14]. Most describe inadequate pain control rather than opioid toxicity, consistent with the predicted pharmacokinetic interaction. No serious adverse events (respiratory depression, overdose) have been attributed to this combination in the post-marketing data to date.

Tramadol: An Additional Pharmacodynamic Concern

Beyond the CYP3A4 interaction, tramadol carries a unique risk in the context of liver disease. Tramadol lowers the seizure threshold. Patients with MASH frequently have metabolic comorbidities (type 2 diabetes, insulin resistance) that independently increase seizure susceptibility [15]. The FDA label for tramadol warns against use in patients with hepatic impairment, recommending extended dosing intervals when use cannot be avoided [16].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on analgesic use in chronic liver disease recommends that tramadol be used at reduced doses (50% of standard) in patients with Child-Pugh class B or C cirrhosis [17]. While most patients initiating resmetirom have pre-cirrhotic fibrosis (F2-F3), the combination of CYP3A4 induction (reducing tramadol efficacy) and hepatic vulnerability (increasing tramadol toxicity risk at higher doses) creates a narrow therapeutic window that makes tramadol a less favorable choice in this population.

Oxycodone vs. Hydrocodone: Which Is Preferred With Resmetirom?

Neither opioid has a clear pharmacokinetic advantage. Both depend on CYP3A4 for a substantial fraction of their clearance. A 2021 systematic review in the Journal of Pain Research found no clinically significant difference in CYP3A4 sensitivity between the two agents when co-administered with moderate inducers [18].

Practical considerations may favor one over the other. Oxycodone is available in abuse-deterrent formulations that provide more predictable absorption kinetics, which may help maintain steady-state levels even when metabolic clearance is increased. Hydrocodone combination products (hydrocodone/acetaminophen) introduce additional hepatotoxicity risk from acetaminophen in patients whose livers are already compromised by MASH [19]. The FDA advises limiting acetaminophen to 2 g/day in patients with liver disease, a threshold that can be reached quickly with standard hydrocodone/acetaminophen dosing [20].

Dr. Mary Rinella, hepatologist at the University of Chicago and co-author of the AASLD MASH guidance, has stated: "In patients with steatohepatitis, we prefer single-entity opioid formulations when opioids are necessary, avoiding combination products that add hepatotoxic burden" [21].

Non-Opioid Alternatives Worth Discussing With Your Prescriber

Given the interaction complexity, patients and prescribers should consider whether non-opioid analgesia might be sufficient. Acetaminophen monotherapy (at liver-appropriate doses of 2 g/day or less) remains first-line for mild-to-moderate pain in chronic liver disease [17]. Topical NSAIDs (diclofenac gel) avoid first-pass hepatic metabolism. Duloxetine, a serotonin-norepinephrine reuptake inhibitor with demonstrated efficacy in osteoarthritis pain, is metabolized primarily by CYP1A2 rather than CYP3A4, making it largely unaffected by resmetirom's enzyme induction [22].

For patients who require opioid-level analgesia, buprenorphine (transdermal or buccal) offers a pharmacokinetic profile that may be more favorable in this context. While buprenorphine is a CYP3A4 substrate, its high receptor affinity and ceiling effect on respiratory depression provide a wider safety margin [23]. A 2022 study in Pain Medicine reported stable analgesic outcomes with transdermal buprenorphine in patients receiving moderate CYP3A4 inducers, though the study did not include resmetirom specifically [24].

What Patients Should Know: Practical Counseling Points

If you are prescribed Rezdiffra and currently take oxycodone, hydrocodone, or tramadol, several steps can protect your safety. Tell every prescriber (your hepatologist, pain specialist, and primary care physician) about all medications you take. Do not adjust your opioid dose on your own if you notice changes in pain control after starting or stopping resmetirom. Keep a pain diary during the first month of co-administration so your prescriber has objective data for dose decisions.

Watch for signs that your opioid may be less effective: returning pain at times when it was previously controlled, needing breakthrough doses more frequently, or waking from sleep due to pain. Conversely, if resmetirom is stopped, watch for signs of opioid excess: unusual drowsiness, slowed breathing, confusion, or dizziness upon standing.

The FDA MedWatch program accepts voluntary reports of suspected drug interactions at fda.gov/safety/medwatch. Reporting helps build the post-marketing safety profile for newer drugs like resmetirom [14].

Liver Function Monitoring During Co-Administration

Both resmetirom and opioids require hepatic monitoring, though for different reasons. Resmetirom's label mandates ALT, AST, and total bilirubin measurement before initiation, monthly for the first 6 months, and every 3 months thereafter [2]. Opioids, particularly acetaminophen-containing formulations, require periodic hepatic panel review in patients with underlying liver disease [20].

A reasonable consolidated monitoring schedule: baseline comprehensive metabolic panel before starting resmetirom, repeat at weeks 2 and 4 (coinciding with peak CYP3A4 induction), monthly through month 6, then every 3 months. If ALT exceeds 5 times the upper limit of normal, the Rezdiffra label recommends dose reduction or discontinuation [2]. Any such change will alter the degree of CYP3A4 induction and require corresponding reassessment of opioid dosing.

Thyroid function (TSH, free T4) should be checked at baseline and 4 to 8 weeks after initiation, per the prescribing information, since resmetirom's THR-β agonism can suppress TSH [2]. This is independent of the opioid interaction but relevant to overall patient safety during a period of medication adjustment.

Patients taking resmetirom 100 mg daily (indicated for body weight ≥100 kg) receive a higher degree of CYP3A4 induction than those on 80 mg [2]. Opioid dose adjustments may need to be proportionally larger in this group.